Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment

NCT01382706 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT01382706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01382706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Terminated
Start date
June 13, 2011
Completion date
December 15, 2017
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent bladder cancer, stage iii bladder cancer, stage iv bladder cancer, transitional cell carcinoma of the bladder